2011
Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody
Santin A, Bellone S, Varughese J, Cocco E, Ratner E, Silasi D, Rutherford T, Schwartz P, Azodi M, Pecorelli S. Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Gynecologic Oncology 2011, 120: s6-s7. DOI: 10.1016/j.ygyno.2010.12.018.Peer-Reviewed Original ResearchUterine serous papillary carcinomaSerous papillary carcinomaCell surface markersPapillary carcinomaSurface markersMonoclonal antibodies
2009
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British Journal Of Cancer 2009, 101: 335-341. PMID: 19536090, PMCID: PMC2720219, DOI: 10.1038/sj.bjc.6605129.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaSerum amyloid AUSPC patientsBenign diseaseSAA concentrationsNovel biomarkersPrimary USPC cell linesUterine serous papillary cancerSerum SAALiver-secreted proteinsNormal healthy femalesUSPC cell linesEarly disease recurrenceSerous papillary carcinomaNormal endometrial tissuesExpression levelsProtein expression levelsEndometrial cancerAggressive variantHealthy womenEndometrial tissuePapillary cancerSerum biomarkersAmyloid AHealthy groupPotential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma
Santin A, Bellone S, El-Sahwi K, Buza N, Tavassoli F, Silasi D, Azodi M, Schwartz P, Rutherford T, Pecorelli S. Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma. Journal Of Clinical Oncology 2009, 27: e16502-e16502. DOI: 10.1200/jco.2009.27.15_suppl.e16502.Peer-Reviewed Original ResearchUterine serous papillary carcinomaPrimary USPC cell linesAntibody-dependent cellular cytotoxicityUSPC cell linesNormal endometrial cellsSerous papillary carcinomaComplement-dependent cytotoxicityHuman monoclonal antibodyEpithelial cell adhesion moleculeEndometrial cellsCell adhesion moleculePapillary carcinomaTherapeutic strategiesCell linesChromium release cytotoxicity assaysFlow cytometryEpCAM expressionMonoclonal antibodiesDependent cytotoxicityAdhesion moleculesRelease cytotoxicity assayStandard treatment modalityDependent cellular cytotoxicityUterine serous carcinomaAggressive biologic behavior
2005
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal Of Cancer 2005, 92: 1561-1573. PMID: 15785748, PMCID: PMC2362016, DOI: 10.1038/sj.bjc.6602480.Peer-Reviewed Original ResearchConceptsUterine serous papillary cancerNormal endometrial cellsEndometrial cancerAggressive variantClaudin-4Normal endometrial epithelial cellsUterine serous papillary carcinomaAdhesion moleculesNovel therapeutic markerCommon gynecologic tumorsSerous papillary carcinomaParaffin-embedded specimensEndometrial epithelial cellsL1 cell adhesion moleculeType-specific therapiesRas homolog gene familyQuantitative RT-PCRScalar dosesGynecologic tumorsPapillary cancerEndometrial cellsInterleukin-6Cell adhesion moleculeNovel molecular markersPapillary carcinoma
2004
GENE EXPRESSION FINGERPRINT OF UTERINE SEROUS PAPILLARY CARCINOMA: IDENTIFICATION OF NOVEL MOLECULAR MARKERS FOR UTERINE SEROUS CANCER DIAGNOSIS AND THERAPY
Santin A, Bellone S, Cane' S, Palmieri M, Bignotti E, Anfossi S, Thomas M, Roman J, Kay H, Burnett A, O'Brien T, Cannon M, John S, Zhan F, Tian E, Pecorelli S. GENE EXPRESSION FINGERPRINT OF UTERINE SEROUS PAPILLARY CARCINOMA: IDENTIFICATION OF NOVEL MOLECULAR MARKERS FOR UTERINE SEROUS CANCER DIAGNOSIS AND THERAPY. International Journal Of Gynecological Cancer 2004, 14: 2.3-2. DOI: 10.1136/ijgc-00009577-200409001-00006.Peer-Reviewed Original ResearchDiscrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. British Journal Of Cancer 2004, 90: 1814-1824. PMID: 15208622, PMCID: PMC2409747, DOI: 10.1038/sj.bjc.6601791.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, PapillaryCells, CulturedCystadenocarcinoma, SerousDiagnosis, DifferentialFemaleFlow CytometryGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedOligonucleotide Array Sequence AnalysisOvarian NeoplasmsReceptor, ErbB-2Reverse Transcriptase Polymerase Chain ReactionUterine NeoplasmsConceptsUterine serous papillary carcinomaGene expressionOverexpressed genesSerous papillary carcinomaGene expression fingerprintGene expression profilingHuman genesC-erbB2 geneExpression fingerprintsMolecular basisExpression profilingPapillary carcinomaOligonucleotide microarraysExpression productsQuantitative RT-PCRGenesClinical tissue samplesProbe setsTwo-fold differenceMore effective treatment modalitiesEffective treatment modalitySerous papillary tumorsPlasminogen activator inhibitorDifferent biological behaviorDevelopment of novel
2002
Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
Santin AD, Bellone S, Ravaggi A, Roman JJ, Pecorelli S, Parham GP, Cannon MJ. Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. British Journal Of Cancer 2002, 86: 151-157. PMID: 11857027, PMCID: PMC2746546, DOI: 10.1038/sj.bjc.6600026.Peer-Reviewed Original ResearchConceptsAutologous tumor cellsUterine serous papillary cancerAutologous dendritic cellsT cellsPatient 1Patient 3Tumor cellsDendritic cellsPapillary cancerOvarian cancerAutologous tumor target cellsTumor lysate-pulsed DCsAnti-HLA class IUterine serous papillary carcinomaColor flow cytometric analysisCancer-specific CD8Cisplatinum-based chemotherapyLumboaortic lymph nodesPapillary cancer patientsTumor-specific toleranceTumor-specific CD8Intracellular cytokine expressionHigh-grade ovarian cancerT lymphocyte responsesStrong cytolytic activity